Welcome to our dedicated page for Medicus Pharma SEC filings (Ticker: MDCX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing Medicus Pharma’s SEC disclosures can feel like decoding lab notes. Clinical endpoints, dose-escalation tables and financing covenants pack the company’s annual report—yet each detail can shift the valuation of this oncology-focused biotech overnight. If you have ever asked, “How do I get Medicus Pharma SEC filings explained simply?” you already know the challenge.
Stock Titan turns those dense documents into clarity. Our AI delivers line-by-line context so understanding Medicus Pharma SEC documents with AI becomes second nature. Need the Medicus Pharma annual report 10-K simplified or to monitor a sudden Medicus Pharma 8-K material events explained? It’s here, refreshed the instant EDGAR posts. Key tools include:
- Real-time alerts for every Medicus Pharma Form 4 insider transactions real-time
- Concise takeaways from each Medicus Pharma quarterly earnings report 10-Q filing
- AI-powered summaries that surface trial milestones, R&D spend and funding rounds
- Downloadable tables covering Medicus Pharma executive stock transactions Form 4
Whether you’re tracking basal-cell carcinoma trial progress or assessing dilution risk, our platform connects the dots. Investors use it to spot buying patterns in Medicus Pharma insider trading Form 4 transactions, compare cash burn across quarters with our Medicus Pharma earnings report filing analysis, or review the Medicus Pharma proxy statement executive compensation before casting votes. No more hunting through PDFs—just precise, AI-driven insight when it matters.
Medicus Pharma Ltd. has filed a prospectus supplement registering up to 1,397,184 common shares and incorporating its latest quarterly report. The company is a clinical-stage biotech developing dissolvable microneedle patches for skin cancers and, through newly acquired Antev, a GnRH antagonist (Teverelix) for prostate-related indications.
As of September 30, 2025, Medicus held $8.7 million in cash and total assets of about $10.0 million, but current liabilities of $10.7 million left shareholders with a deficit of roughly $0.8 million. There were 22,029,144 common shares outstanding as of November 11, 2025, and the Nasdaq share price was $2.26 on November 13, 2025.
The company reported a net loss of $15.98 million for the quarter and $27.26 million for the nine months ended September 30, 2025, driven by higher general and administrative and R&D spending and an $8.72 million in-process R&D charge related to Teverelix. Operations have been funded by equity offerings, warrant exercises, a standby equity purchase agreement and new debentures, and management discloses substantial doubt about the ability to continue as a going concern without additional capital.
Medicus Pharma Ltd. is registering 2,260,000 common shares issuable upon the exercise of warrants under its Form S-1, via a new prospectus supplement that incorporates its Quarterly Report on Form 10-Q for the period ended September 30, 2025. The company reported a net loss attributable to common shareholders of
Medicus Pharma Ltd. is registering 1,115,500 common shares issuable upon exercise of existing public warrants. The warrants have a $4.64 exercise price and expire on November 15, 2029, while the common shares and warrants trade on Nasdaq under "MDCX" and "MDCXW." As of November 11, 2025, the company had 22,029,144 common shares outstanding.
For the nine months ended September 30, 2025, Medicus reported a net loss of $27.3 million, driven by $26.6 million in operating expenses, including $12.7 million in general and administrative costs, $5.1 million in R&D, and an $8.7 million in-process R&D charge from the Antev acquisition. Shareholders’ equity shifted to a deficit of about $0.8 million despite multiple equity raises and warrant exercises.
Cash and cash equivalents were $8.7 million against a working capital deficit and debentures of $6.8 million. Management discloses substantial doubt about the company’s ability to continue as a going concern and highlights reliance on additional financings, including a standby equity purchase agreement of up to $15 million, warrant exercises, and other capital sources to fund ongoing clinical programs.
Medicus Pharma Ltd. has filed a prospectus supplement covering up to 7,500,000 common shares under its Form S-1, updating the offering with new quarterly information. The attached Form 10-Q shows a clinical-stage biotech expanding its pipeline but generating substantial losses as it funds development and acquisitions.
For the nine months ended September 30, 2025, the company recorded a net loss of $27,259,804, driven by $26,568,702 in operating expenses that include $8,717,475 of in-process R&D expense from the Antev acquisition, higher general and administrative costs, and increased research and development spending. Cash and cash equivalents were $8,662,091 as of September 30, 2025.
Medicus raised capital through a Regulation A unit offering, a June 2025 public offering, warrant exercises, a standby equity purchase agreement and new debentures, but still reported a shareholders’ deficit and a working capital deficit. The company discloses substantial doubt about its ability to continue as a going concern without additional financing. As of November 11, 2025, it had 22,029,144 common shares issued and outstanding.
Medicus Pharma Ltd. filed an 8-K reporting that it furnished a press release covering its financial and operating results for the quarter ended September 30, 2025, along with other corporate updates. The press release is provided as Exhibit 99.1.
The company’s securities listed on the NASDAQ Capital Market include common shares (ticker MDCX) and warrants (ticker MDCXW), with each warrant exercisable for one common share at an exercise price of $4.64 per share.
Medicus Pharma filed a prospectus supplement to its Form S-1 covering up to 3,710,000 common shares. The supplement attaches a Current Report on Form 8-K.
The 8-K details recent sales of 1,088,048 common shares to Yorkville under the Standby Equity Purchase Agreement, for approximate aggregate consideration of $2,526,364, across multiple issuances from September 8 to October 16, 2025. The company states it has used part of the net proceeds to prepay a portion of a debenture outstanding with Yorkville.
Medicus Pharma’s common shares trade on Nasdaq as MDCX; the last reported sales price was $2.41 on October 16, 2025. The company is an emerging growth company under SEC rules.
Medicus Pharma filed a prospectus supplement covering 2,260,000 common shares issuable upon the exercise of warrants. The company’s common shares and the public warrants (exercise price $4.64, expiring November 15, 2029) trade on Nasdaq as MDCX and MDCXW. On October 16, 2025, the last reported prices were $2.41 for the shares and $0.90 for the warrants.
Attached, a Current Report details recent sales under a Standby Equity Purchase Agreement with Yorkville. Between September 8 and October 16, 2025, the company sold 1,088,048 common shares to Yorkville for aggregate consideration of $2,526,364, in transactions exempt from registration under Section 4(a)(2). The company used part of the net proceeds to prepay a portion of a debenture outstanding with Yorkville.
Medicus Pharma Ltd. filed a prospectus supplement updating its S-1 to cover 1,115,500 common shares issuable upon the exercise of warrants. The supplement incorporates a new Form 8-K.
The company also reported under the SEPA with Yorkville that it sold 1,088,048 common shares across multiple dates for approximately $2,526,364 in aggregate consideration, and used part of the net proceeds to prepay a portion of a debenture with Yorkville. The common shares and public warrants trade on Nasdaq as MDCX and MDCXW; on October 16, 2025, last reported prices were $2.41 and $0.90, respectively. The public warrants have a $4.64 exercise price and expire on November 15, 2029.
Medicus Pharma Ltd. (MDCX) reported unregistered sales of 1,088,048 common shares for approximately $2,526,364 in aggregate consideration under its Standby Equity Purchase Agreement (SEPA) with Yorkville. The sales occurred between September 8 and October 16, 2025, at prices ranging from $1.7961 to $2.7698 per share.
The company stated it has used part of the net proceeds to prepay a portion of a debenture outstanding with Yorkville. The shares were issued in reliance on Section 4(a)(2) of the Securities Act. The SEPA permits additional share purchases by Yorkville from time to time, subject to its conditions and limitations, and Yorkville may resell purchased shares pursuant to an effective registration statement.
FAQ
What is the current stock price of Medicus Pharma (MDCX)?
What is the market cap of Medicus Pharma (MDCX)?
